Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma

To evaluate cardiovascular safety of two new inhaled fixed-dose combinations for treatment of asthma: (i) the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) mometasone furoate/indacaterol acetate (MF/IND), (ii) the ICS/LABA/long-acting muscarinic antagonist (LAMA) MF/IND/glycopyrronium bromide (GLY).

Source: Respiratory Medicine - January 27, 2021 Category: Respiratory Medicine Authors: Emil Scosyrev, Richard van Zyl-Smit, Huib Kerstjens, Christian Gessner, Oliver Kornmann, Devendra Jain, Elodie Aubrun, Peter D ’Andrea, Motoi Hosoe, Abhijit Pethe, Dominic Brittain Tags: Original Research Source Type: research